Understanding Heart Disease

Cardiovascular disease kills more people globally than any other condition, accounting for roughly 17.9 million deaths per year according to the World Health Organization. Within this broad category, two forms are especially relevant to the conversation about tirzepatide: atherosclerotic cardiovascular disease (ASCVD), which includes heart attacks and strokes caused by plaque in the arteries, and heart failure, where the heart cannot pump blood effectively enough to meet the body's needs.

The connection between obesity and heart disease is bidirectional. Obesity promotes atherosclerosis through inflammation, insulin resistance, dyslipidemia, and hypertension. At the same time, excess weight strains the heart muscle itself, leading to structural changes (cardiac remodeling) that can progress to heart failure. A 2018 analysis in the European Heart Journal by Kenchaiah et al. found that for every unit increase in BMI, the risk of heart failure increased by 5 percent in men and 7 percent in women. obesity and heart disease

This dual burden makes therapies that address both weight and cardiovascular health particularly appealing.

What the Research Shows

The SUMMIT Trial: Heart Failure with Preserved Ejection Fraction

The SUMMIT trial, presented at the American Heart Association Scientific Sessions in 2024, studied tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. HFpEF accounts for roughly half of all heart failure cases and has been one of the most treatment-resistant conditions in cardiology.

Tirzepatide reduced the composite of cardiovascular death or worsening heart failure events by 38 percent compared to placebo (HR 0.62, 95% CI 0.48-0.81). Heart failure hospitalizations and urgent visits decreased substantially. Patients also experienced a 7.5-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, indicating clinically meaningful symptom relief.

The magnitude of this benefit was striking. Few therapies have shown this level of efficacy in HFpEF, making tirzepatide potentially the most impactful intervention for this population in over a decade.

SURMOUNT-MMO: The Pending Cardiovascular Outcomes Trial

Eli Lilly initiated SURMOUNT-MMO, a dedicated cardiovascular outcomes trial, enrolling approximately 15,000 adults with overweight or obesity and established cardiovascular disease or multiple cardiovascular risk factors but without diabetes. The primary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results are anticipated around 2027.

Until SURMOUNT-MMO reports, we cannot definitively say whether tirzepatide reduces heart attacks and strokes in the same way that semaglutide did in the SELECT trial. However, the robust metabolic improvements seen in SURMOUNT-1 and SURMOUNT-2, combined with the SUMMIT heart failure data, provide strong biological plausibility.

Metabolic Markers Relevant to Cardiovascular Protection

Across the SURMOUNT trials, tirzepatide improved virtually every modifiable cardiovascular risk factor. At the 15 mg dose: systolic blood pressure decreased by 7.2 mmHg, triglycerides decreased by 27 percent, high-sensitivity CRP decreased by approximately 35 to 40 percent, and insulin resistance (HOMA-IR) improved by approximately 60 percent. These changes collectively paint a picture of comprehensive cardiovascular risk reduction.

How Tirzepatide May Help

Tirzepatide's dual GLP-1/GIP receptor agonism provides several potential pathways for cardiovascular protection. tirzepatide mechanism of action

Inflammation reduction: Chronic inflammation is a driver of both plaque instability and heart failure progression. Tirzepatide's 35 to 40 percent reduction in CRP is comparable to what was seen with canakinumab in the CANTOS trial, which proved that reducing inflammation independently lowers cardiovascular event rates. While the mechanism differs (tirzepatide works through metabolic improvement rather than direct IL-1 beta blockade), the magnitude of CRP reduction suggests a meaningful anti-inflammatory contribution.

Cardiac remodeling: Obesity causes the heart to remodel: the left ventricle thickens, filling pressures rise, and diastolic function deteriorates. Weight loss reverses some of these changes. A cardiac MRI sub-study within the STEP-HFpEF program (using semaglutide, a closely related agent) showed reductions in left ventricular mass and improved diastolic filling. Similar effects are expected with tirzepatide given the even greater weight loss it produces.

Improved endothelial function: Both GLP-1 and GIP receptor activation have been associated with enhanced nitric oxide bioavailability in blood vessels, improving vasodilation and reducing endothelial dysfunction.

Epicardial fat reduction: Epicardial adipose tissue (fat surrounding the heart) is directly inflammatory and contributes to coronary artery disease and heart failure. Weight loss with incretin-based therapies has been shown to substantially reduce epicardial fat volume. A study by Iacobellis et al. demonstrated that GLP-1 agonist therapy reduced epicardial fat thickness by 15 to 20 percent.

Important Safety Information

Tirzepatide (as Mounjaro) is FDA-approved for type 2 diabetes. As Zepbound, it is approved for chronic weight management. It does not yet have an FDA-approved cardiovascular indication, though the SUMMIT data may support future applications.

In patients with heart disease, healthcare providers should be alert to several considerations. Dehydration from GI side effects (nausea, vomiting, diarrhea) can be particularly problematic in patients on diuretics, ACE inhibitors, or ARBs, as the combination may impair kidney function.

The 2 to 4 bpm increase in resting heart rate seen with incretin-based therapies has not been associated with adverse outcomes in trials, but patients with atrial fibrillation or other arrhythmias should be monitored.

Tirzepatide carries a boxed warning about thyroid C-cell tumors in rodent studies and is contraindicated in patients with medullary thyroid carcinoma or MEN2. tirzepatide safety information

Who Might Benefit

Based on current evidence, tirzepatide may be most valuable for cardiovascular health in these patient groups:

• Adults with HFpEF and obesity, where the SUMMIT trial data provide the strongest evidence
• Patients with multiple cardiovascular risk factors (hypertension, dyslipidemia, insulin resistance) driven by obesity
• Adults with type 2 diabetes and cardiovascular risk, where Mounjaro addresses glucose while potentially protecting the heart
• People with metabolic syndrome who need comprehensive cardiometabolic risk reduction

For patients with established ASCVD (prior heart attack or stroke) who do not have diabetes, the evidence for cardiovascular event reduction is stronger with semaglutide (based on SELECT) until SURMOUNT-MMO results become available.

How to Talk to Your Doctor

The conversation about tirzepatide and heart disease will depend on your specific cardiovascular condition:

• If you have HFpEF and obesity, reference the SUMMIT trial and its 38 percent reduction in cardiovascular death or worsening heart failure
• If you have multiple risk factors, discuss your overall cardiometabolic burden and whether tirzepatide could address several issues simultaneously
• If you have established ASCVD, acknowledge that SURMOUNT-MMO is still ongoing and discuss whether semaglutide (with its completed SELECT data) might be more appropriate in the interim
• Ask about coordination between your cardiologist and primary care provider or endocrinologist to ensure all aspects of your cardiovascular health are managed coherently

coordinating cardiac and metabolic care

Frequently Asked Questions

Has tirzepatide been proven to prevent heart attacks?

Not yet definitively. The SURMOUNT-MMO cardiovascular outcomes trial is ongoing and expected to report around 2027. The SUMMIT trial showed reduced heart failure events, but a dedicated ASCVD outcomes trial is needed to confirm whether tirzepatide prevents heart attacks and strokes.

How does tirzepatide compare to semaglutide for heart disease?

Semaglutide currently has stronger evidence for ASCVD event reduction (via SELECT). Tirzepatide has stronger early data for heart failure with preserved ejection fraction (via SUMMIT). Both produce substantial weight loss and metabolic improvement. The choice between them should be guided by your specific cardiovascular condition and overall clinical profile.

Is tirzepatide safe for people who have had a heart attack?

Tirzepatide has been studied in patients with cardiovascular risk factors and appears generally well-tolerated. However, patients recovering from a recent heart attack should discuss timing and safety with their cardiologist, paying particular attention to hydration status and the potential for GI side effects to interfere with medication adherence and nutrition.

Taking the Next Step

Tirzepatide's cardiovascular story is still being written, but the early chapters are promising. The SUMMIT trial marks a potential breakthrough for HFpEF, and SURMOUNT-MMO may establish tirzepatide alongside semaglutide as a proven cardiovascular protector.

At FormBlends, we follow the science as it unfolds. Stay informed through our resources, and bring your questions to your healthcare team. GLP-1 medications overview